NAGIOS: RODERIC FUNCIONANDO

Arginine Vasopressin Enhances Sympathetic Constriction Through the V1 Vasopressin Receptor in Human Saphenous Vein

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Arginine Vasopressin Enhances Sympathetic Constriction Through the V1 Vasopressin Receptor in Human Saphenous Vein

dc.contributor.author	Medina Bessó, Pascual
dc.contributor.author	Acuña Torre, Antonio
dc.contributor.author	Martínez León, Juan Bautista
dc.contributor.author	Otero, Eduardo
dc.contributor.author	Vila Salinas, José María
dc.contributor.author	Aldasoro Celaya, Martín
dc.contributor.author	Lluch López, Salvador
dc.date.accessioned	2011-08-19T09:15:40Z
dc.date.available	2011-08-19T09:15:40Z
dc.date.issued	1998
dc.identifier.citation	MEDINA BESSO, Pascual ; Acuña Torre, Antonio ; Martinez Leon, Juan Baustista ; Otero, Eduardo ; Vila Salinas, José M ; Aldasoro Celaya, Martin ; Lluch Lopez, Salvador, 1998, Arginine Vasopressin Enhances Sympathetic Constriction Through the V1 Vasopressin Receptor in Human Saphenous Vein, Circulation, vol. 97, no. 9, p. 865-870	en
dc.identifier.uri	http://hdl.handle.net/10550/20055
dc.description.abstract	Background—Arginine vasopressin (AVP) not only acts directly on blood vessels through V1 receptor stimulation but also may modulate adrenergic-mediated responses in animal experiments in vivo and in vitro. The aim of the present study was to investigate whether AVP can contribute to an abnormal adrenergic constrictor response of human saphenous veins. Methods and Results—Saphenous vein rings were obtained from 32 patients undergoing coronary artery bypass surgery. The vein rings were suspended in organ bath chambers for isometric recording of tension. AVP (331029 mol/L) enhanced the contractions elicited by electrical field stimulation at 1, 2, and 4 Hz (by 80%, 70%, and 60%, respectively) and produced a leftward shift of the concentration-response curve to norepinephrine (half-maximal effective concentration decreased from 6.8731027 to 1.0431027 mol/L; P,.05). The V1 vasopressin receptor antagonist d(CH2)5Tyr(Me)AVP (1026 mol/L) prevented the potentiation evoked by AVP. The selective V1 receptor agonist [Phe,2 Orn8]-vasotocin (331029 mol/L) induced potentiation of electrical stimulation– evoked responses, which was also inhibited in the presence of the V1 receptor antagonist (1026 mol/L). In contrast, the V2 receptor agonist desmopressin (1029 to 1027 mol/L) did not modify neurogenic responses, and the V2 receptor antagonist [d(CH2)5, D-Ile,2 Ile,4 Arg8]-vasopressin (1028 to 1026 mol/L) did not prevent the potentiation induced by AVP. The dihydropyridine calcium antagonist nifedipine (1026 mol/L) did not affect the potentiating effect of AVP. Conclusions—The results suggest that low concentrations of AVP facilitate sympathetic neurotransmission and potentiate constrictor effects of norepinephrine in human saphenous veins. These effects appear to be mediated by V1 receptor stimulation and are independent of calcium entry through dihydropyridine calcium channels. Thus, AVP may contribute to vascular mechanisms involved in acute ischemic syndromes associated with venous grafts, particularly if the sympathetic nervous system is activated. (Circulation. 1998;97:865-870.)	en
dc.language.iso	en	en
dc.subject	Veins ; Arginine vasopressin ; Electrical stimulation ; Norepinephrine	en
dc.title	Arginine Vasopressin Enhances Sympathetic Constriction Through the V1 Vasopressin Receptor in Human Saphenous Vein	en
dc.type	journal article	es_ES
dc.subject.unesco	UNESCO::CIENCIAS MÉDICAS	en
dc.subject.unesco	UNESCO::CIENCIAS MÉDICAS ::Medicina interna	en
dc.identifier.idgrec	009788	en
dc.type.hasVersion	VoR	es_ES
dc.identifier.url	http://circ.ahajournals.org/cgi/reprint/97/9/865	en